Skip to main content
Coronary Artery DiseaseHeart and circulationDrugPhase 4

What this study is

The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.

What's being tested

  • Liposomal bupivacaine

    Intervention · DRUG

    Patients undergoing isolated coronary artery bypass grafting will receive a stellate ganglion block using liposomal bupivacaine prior to surgery

  • Placebo

    Intervention · DRUG

    Patients undergoing isolated coronary artery bypass grafting will receive a saline placebo injection to the stellate ganglion prior to surgery

Study details

Official title
Effectiveness Of Liposomal Bupivacaine Stellate Ganglion Blockade In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery: A Randomized Placebo-Controlled Trial
Sponsor
Mayo Clinic
Conditions
Coronary Artery Disease · Atrial Fibrillation
Enrolling
450 people
Starts
2026-09-14
Est. completion
2030-09
Design
Double-blind, randomized, parallel groups, Phase 4
Record
View on ClinicalTrials.gov ↗